| General Information | |
|---|---|
| ZINC ID | ZINC000000862389 |
| Molecular Weight (Da) | 440 |
| SMILES | Cc1ccc(C(=O)Oc2ccccc2Br)cc1S(=O)(=O)N1CCOCC1 |
| Molecular Formula | C18Br1N1O5S1 |
| Action | Agonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 101.053 |
| HBA | 5 |
| HBD | 0 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 26 |
| LogP | 3.301 |
| Activity (Ki) in nM | 31.6228 |
| Polar Surface Area (PSA) | 81.29 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | + |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | - |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | - |
| Cyp2c9 inhibition | - |
| Cyp2c19 inhibition | + |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | - |
| Acute oral toxicity | - |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | - |
| Androgen receptor binding | - |
| Plasma protein binding | 1.143 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 12 |
| Fraction csp3 | 0.28 |
| Ilogp | 3.2 |
| Xlogp3 | 3.16 |
| Wlogp | 3.7 |
| Mlogp | 2.44 |
| Silicos-it log p | 2.87 |
| Consensus log p | 3.07 |
| Esol log s | -4.57 |
| Esol solubility (mg/ml) | 0.0118 |
| Esol solubility (mol/l) | 0.0000268 |
| Esol class | Moderately |
| Ali log s | -4.54 |
| Ali solubility (mg/ml) | 0.0128 |
| Ali solubility (mol/l) | 0.000029 |
| Ali class | Moderately |
| Silicos-it logsw | -5.84 |
| Silicos-it solubility (mg/ml) | 0.000638 |
| Silicos-it solubility (mol/l) | 0.00000145 |
| Silicos-it class | Moderately soluble |
| Pgp substrate | |
| Log kp (cm/s) | -6.74 |
| Lipinski number of violations | 0 |
| Ghose number of violations | 0 |
| Veber number of violations | 0 |
| Egan number of violations | 0 |
| Muegge number of violations | 0 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 1 |
| Leadlikeness number of violations | 1 |
| Synthetic accessibility | 3.03 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -5.257 |
| Logd | 3.464 |
| Logp | 3.758 |
| F (20%) | 0.886 |
| F (30%) | 0.013 |
| Mdck | - |
| Ppb | 98.45% |
| Vdss | 0.542 |
| Fu | 2.87% |
| Cyp1a2-inh | 0.602 |
| Cyp1a2-sub | 0.095 |
| Cyp2c19-inh | 0.919 |
| Cyp2c19-sub | 0.191 |
| Cl | 2.928 |
| T12 | 0.382 |
| H-ht | 0.135 |
| Dili | 0.98 |
| Roa | 0.232 |
| Fdamdd | 0.151 |
| Skinsen | 0.063 |
| Ec | 0.003 |
| Ei | 0.186 |
| Respiratory | 0.049 |
| Bcf | 0.596 |
| Igc50 | 4.189 |
| Lc50 | 5.065 |
| Lc50dm | 4.938 |
| Nr-ar | 0.06 |
| Nr-ar-lbd | 0.02 |
| Nr-ahr | 0.319 |
| Nr-aromatase | 0.855 |
| Nr-er | 0.409 |
| Nr-er-lbd | 0.012 |
| Nr-ppar-gamma | 0.017 |
| Sr-are | 0.56 |
| Sr-atad5 | 0.01 |
| Sr-hse | 0.016 |
| Sr-mmp | 0.656 |
| Sr-p53 | 0.013 |
| Vol | 368.5 |
| Dense | 1.191 |
| Flex | 0.238 |
| Nstereo | 0 |
| Nongenotoxic carcinogenicity | 1 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 0 |
| Nonbiodegradable | 1 |
| Skin sensitization | 2 |
| Acute aquatic toxicity | - |
| Toxicophores | 0 |
| Qed | 0.54 |
| Synth | 2.095 |
| Fsp3 | 0.278 |
| Mce-18 | 44.609 |
| Natural product-likeness | -1.746 |
| Alarm nmr | 3 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | - |
| Gsk | Rejected |
| Goldentriangle | Accepted |